adalimumab

1
Reactions 1484, p5 - 18 Jan 2014 S Adalimumab Ischaemic central retinal vein occlusion and subsequent neovascular glaucoma: case report A 36-year-old man developed ischaemic central retinal vein occlusion (CRVO) and subsequent neovascular glaucoma while receiving adalimumab. The man presented with loss of vision in his left eye. He had a history of psoriasis, and approximately 2 months earlier, he had started receiving adalimumab 40mg every 2 weeks [route not stated]. After his fifth dose of adalimumab, he suddenly developed blurred vision in his left eye. Fundus photographs showed intraretinal haemorrhages and tortuosity and dilatation of retinal veins with cotton-wool spots. Upon fluorescein angiography, there was delayed dye filling of the retinal veins, with patches of hypofluorescence in the early phase and leakages of dye in the late phase. Optical coherence tomography found retinal swelling at the foveal region. He was diagnosed with ischaemic CRVO in his left eye. Adalimumab was withdrawn; however, the man subsequently developed neovascular glaucoma. At follow-up 5 months later, the visual acuity of his left eye was hand- motion vision only. Author comment: "In our patient, the temporal relationship between CRVO and the adalimumab [therapy] raises the possibility of a causative correlation." Hsu C-K, et al. Central retinal vein occlusion and subsequent neovascular glaucoma after adalimumab treatment for psoriasis. Clinical and Experimental Dermatology 39: 72-73, No. 1, Jan 2014. Available from: URL: http:// dx.doi.org/10.1111/ced.12158 - Taiwan 803098079 1 Reactions 18 Jan 2014 No. 1484 0114-9954/14/1484-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved

Upload: pavel

Post on 23-Dec-2016

218 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Adalimumab

Reactions 1484, p5 - 18 Jan 2014

SAdalimumab

Ischaemic central retinal vein occlusion andsubsequent neovascular glaucoma: case report

A 36-year-old man developed ischaemic central retinal veinocclusion (CRVO) and subsequent neovascular glaucomawhile receiving adalimumab.

The man presented with loss of vision in his left eye. He hada history of psoriasis, and approximately 2 months earlier, hehad started receiving adalimumab 40mg every 2 weeks [routenot stated]. After his fifth dose of adalimumab, he suddenlydeveloped blurred vision in his left eye. Fundus photographsshowed intraretinal haemorrhages and tortuosity anddilatation of retinal veins with cotton-wool spots. Uponfluorescein angiography, there was delayed dye filling of theretinal veins, with patches of hypofluorescence in the earlyphase and leakages of dye in the late phase. Optical coherencetomography found retinal swelling at the foveal region. He wasdiagnosed with ischaemic CRVO in his left eye.

Adalimumab was withdrawn; however, the mansubsequently developed neovascular glaucoma. At follow-up5 months later, the visual acuity of his left eye was hand-motion vision only.

Author comment: "In our patient, the temporalrelationship between CRVO and the adalimumab [therapy]raises the possibility of a causative correlation."Hsu C-K, et al. Central retinal vein occlusion and subsequent neovascularglaucoma after adalimumab treatment for psoriasis. Clinical and ExperimentalDermatology 39: 72-73, No. 1, Jan 2014. Available from: URL: http://dx.doi.org/10.1111/ced.12158 - Taiwan 803098079

1

Reactions 18 Jan 2014 No. 14840114-9954/14/1484-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved